Should I buy or sell Zoetis stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares. View ZTS analyst ratings or view top-rated stocks .

What is Zoetis' stock price target for 2024?

8 brokerages have issued 12-month price objectives for Zoetis' shares. Their ZTS share price targets range from $200.00 to $260.00. On average, they predict the company's stock price to reach $223.78 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts .

How have ZTS shares performed in 2024?

Zoetis' stock was trading at $197.37 on January 1st, 2024. Since then, ZTS shares have decreased by 0.8% and is now trading at $195.7250. View the best growth stocks for 2024 here .

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ZTS earnings forecast .

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Tuesday, February 13th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings data on Tuesday, August, 8th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.10. The company had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.16 billion. Zoetis had a trailing twelve-month return on equity of 52.22% and a net margin of 27.24%. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.20 earnings per share. Read the conference call transcript .

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Tuesday, February 6th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share on Tuesday, June 4th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Thursday, April 18th. Read our dividend analysis for ZTS .

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.73 per share and currently has a dividend yield of 0.88%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 35.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 29.03% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for ZTS .

What ETFs hold Zoetis' stock?

ETFs with the largest weight of Zoetis (NYSE:ZTS) stock in their portfolio include ProShares Pet Care ETF (PAWZ) , VanEck Agribusiness ETF (MOO) , iShares U.S. Pharmaceuticals ETF (IHE) , VanEck Pharmaceutical ETF (PPH) , SPDR S&P Pharmaceuticals ETF (XPH) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Future Fund Long/Short ETF (FFLS) .

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com . Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Hawkins (HWKN) , Aegean Marine Petroleum Network (ANW) , Athabasca Oil (ATH) , Micron Technology (MU) , Accenture (ACN) and Transocean (RIG) .

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.72%), Massachusetts Financial Services Co. MA (0.67%), Principal Financial Group Inc. (0.43%), Brown Advisory Inc. (0.40%), Dimensional Fund Advisors LP (0.38%) and California Public Employees Retirement System (0.36%). Insiders that own company stock include Glenn David , Gregory Norden , Heidi C Chen , Kristin C Peck , Robert Edward Kelly , Robert J Polzer , Robert W Scully , Roman Trawicki , Roxanne Lagano and Willie M Reed . View institutional ownership trends .

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o.. Read More

Followed 123 TimesTop Followed

NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

$195.72

-1.37 (-0.70%)

(As of 02/8/2024 ET)

Compare

Today's Range: $195.00
▼
$197.00
50-Day Range: $176.63
▼
$200.09
52-Week Range: $151.03
▼
$201.92

Volume: 1.52 million shs
Average Volume: 1.86 million shs
Market Capitalization: $89.86 billion

P/E Ratio: 39.78
Dividend Yield: 0.88%
Price Target: $223.78

Get Zoetis alerts:

Zoetis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 14.3% Upside
$223.78 Price Target
Short Interest: Healthy
0.60% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -4.66
Upright™ Environmental Score
News Sentiment: 0.77
Based on 15 Articles This Week
Insider Trading: Selling Shares
$3.14 M Sold Last Quarter
Proj. Earnings Growth: 10.17%
From $5.41 to $5.96 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.77 out of 5 stars

Medical Sector

42nd out of 911 stocks

Pharmaceutical Preparations Industry

12th out of 418 stocks

2.5

Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $223.78, Zoetis has a forecasted upside of 14.3% from its current price of $195.73.
Amount of Analyst Coverage
Zoetis has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.60% of the float of Zoetis has been sold short.
Short Interest Ratio / Days to Cover
Zoetis has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zoetis has recently decreased by 8.64%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Yield
Zoetis has a dividend yield of 0.88%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 35.16%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 29.03% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Zoetis has received a -79.93% net impact score from Upright. The largest negative impact of Zoetis in category "GHG emissions" seems to be driven mostly by its "Cattle antibiotics", "Cattle vaccines", "Vaccines for pet animals", "Antibiotics for pet animals", and "Cattle dewormers" products. See details.
Environmental Sustainability
The Environmental Impact score for Zoetis is -4.66.

3.8

News and Social Media Coverage

News Sentiment
Zoetis has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Zoetis this week, compared to 8 articles on an average week.
Search Interest
53 people have searched for ZTS on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
MarketBeat Follows
123 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 28% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,139,405.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
89.47% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 10.17% in the coming year, from $5.41 to $5.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 39.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.82.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 39.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.22.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 20.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZTS Stock News Headlines

February 8, 2024 | finance.yahoo.com

Ahead of Zoetis (ZTS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

February 7, 2024 | finance.yahoo.com

Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know

February 8, 2024 | The Oxford Club (Ad)

Multimillionaire Investor: "Hands Down the Most Lucrative Discovery of My Entire Career"

Peabody Award-winning journalist Bill Tucker sat down with a reclusive multimillionaire trader... 858 miles OUTSIDE of Wall Street... to discuss a revolutionary new trading strategy that involves...One ticker... one trade... every week.The fast-hitting profit potential is extraordinary.

February 7, 2024 | uk.finance.yahoo.com

Zoetis Declares Second Quarter 2024 Dividend

February 6, 2024 | finance.yahoo.com

Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth

February 4, 2024 | americanbankingnews.com

Brokerages Set Zoetis Inc. (NYSE:ZTS) Price Target at $223.78

February 2, 2024 | americanbankingnews.com

Zoetis (NYSE:ZTS) Lowered to "Buy" at StockNews.com

February 1, 2024 | money.usnews.com

Zoetis Inc - Ordinary Shares - Class A

February 8, 2024 | Stansberry Research (Ad)

HUGE BUY ALERT: Move Fast, Musk…

Since 2018, Eric Wade's investment recommendations have averaged 115%. But one investment he just discovered in Phoenix could blow them all away. It involves Elon Musk, Bill Gates, 32 government mandates, and an AI breakthrough... Not to mention a technology that could help you earn $30,000 a year outside the stock market.

January 31, 2024 | finance.yahoo.com

Should We Be Delighted With Zoetis Inc.'s (NYSE:ZTS) ROE Of 45%?